B
Bull
Bull · 25%NAMS
$42.47
Precio del escenario
$24.920
-0.414 (-1.66%)Al cierre
Loading chart…
- High
- 25.430
- Open
- 25.270
- VWAP
- 25.05
- Vol
- 714.36K
- Mkt Cap
- 1.76B
- Low
- 24.800
- Amount
- 17.89M
- EV/EBITDA, TTM
- -1.16
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
AI analysis of NewAmsterdam Pharma Company NV (NAMS)
holdNewAmsterdam Pharma is currently not a strong buy due to its recent performance and financial losses, despite a positive analyst outlook. The current price is $25.9, with a significant year-to-date change of -26.42%. The RSI is at 27.88, indicating it is oversold, which could suggest a potential rebound. However, the company reported a widening net loss of $64.1 million in Q2, which raises concerns about its financial health. The main risk is the ongoing revenue decline, with an 80.7% year-over-year drop in Q2 revenue, which could hinder recovery efforts.
Métricas de valoración
The current forward P/E ratio for NewAmsterdam Pharma Company NV (NAMS) is 0.00, compared to its 5-year average forward P/E of 1.29.
Alphio AI Price Scenarios for NAMS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding NAMS
Cronología de eventos
Noticias
9.508-05seekingalphaNewAmsterdam Pharma Reports Q2 Net Loss of $64.1 Million
8.507-27NASDAQ.COMNewAmsterdam Pharma Receives Positive EU Opinion
8.507-26PRnewswireCHMP Positive Opinion Supports Obicetrapib Market Launch
8.507-25PRnewswireEU CHMP Recommends Obicetrapib for Market Authorization
8.507-24PRnewswireNewAmsterdam and Menarini Receive Positive CHMP Opinion for Ubeslo and Evlarco
NAMS FAQ — answered by Alphio AI
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
NewAmsterdam Pharma is currently not a strong buy due to its recent performance and financial losses, despite a positive analyst outlook. The current price is $25.9, with a significant year-to-date change of -26.42%. The RSI is at 27.88, indicating it is oversold, which could suggest a potential rebound. However, the company reported a widening net loss of $64.1 million in Q2, which raises concerns about its financial health. The main risk is the ongoing revenue decline, with an 80.7% year-over-year drop in Q2 revenue, which could hinder recovery efforts.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.